Edgewise Therapeutics raises $95M to fund muscular-dystrophy drug trials
BOULDER — Edgewise Therapeutics Inc. has more than doubled its previous fundraising rounds by closing a $95 million Series C […]
Source: BizWest
Related Articles
BizWest celebrates 40 years covering business and recognizes 40 iconic leaders who inspired the region’s development.
View related stories: Click here to view the 40th Anniversary supplement. ‘Turnpike’ helps define how economy has changed Wood: Preserving…
Edgewise Therapeutics receives FDA approval for muscular dystrophy drug trials, launches stock offering
BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX) has received authorization from the U.S. Food and Drug Administration to conduct Phase…
Edgewise Therapeutics reports continued successful drug trials, $17.4M loss in third quarter
BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX) reported continued successful drug trials in the third quarter of 2022 as the…
Boulder’s Arpeggio Bioscience raises $17M Series A to bolster drug trials
BOULDER — Arpeggio Bioscience Inc., a preclinical-stage pharmaceutical company founded by University of Colorado Boulder doctoral program graduates, has raised…
Edgewise reports positive interim results from Becker muscular dystrophy treatment trial
BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX), a clinical-stage biopharmaceutical company developing drugs to treat muscular dystrophy, has observed positive…